We are reporting an interesting case of bilateral panuveitis with optic neuritis, after intravesical instillation of BCG. A 70 years old female developed eye changes post maintenance BCG for her Bladder cancer (Carcinoma in situ). After discussion with pulmonary team, it was decided not to start anti-TB medications and to treat her with oral steroids and topical steroids. There was a dramatic improvement in her vision six weeks after the treatment.These patients may have a good visual outcome, as long as the diagnosis and treatment are not delayed.
Introduction
Superficial ladder cancer has been successfully treated with intravesical Bacillus Calmette-Guerin (BCG). In particular carcinoma in Situ (CIS) which is a non-invasive subtype has shown a higher response rate and therefore prompted a more conservative approach to management.1? We are reporting a case of bilateral panuveitis with optic neuritis, after intravesical instillation of BCG. These patients may have a good visual outcome, as long as the diagnosis and treatment are not delayed.
A 70-year-old female was diagnosed with bladder CIS and completed a 6 weeks induction course of BCG intravesically. While she was on maintenance BCG, treatment had to be stopped due to bladder pain. One week after stopping the BCG, she also developed painful eyes for which she was referred to Ophthalmology.
On examination, her visual acuity was 6/18 in left and 6/9 in right. This has deteriorated in both eyes and dropped to 6/24 in the follow up visit. The conjunctiva was injected, and the cornea was swollen. Fundoscopy shows swelling of both optic nerve heads and there was left Vitreous haemorrrhage. A diagnosis of bilateral panuveitis with optic neuritis was made.
Routine investigations included normal FBC, U&Es, LFTs and ESR. Her autoimmune and vasculitis screen was normal except for positive HLA B27 without symptoms and signs of arthritis. Total body CT showed no obvious malignancy. Repeat cystoscopy and biopsy showed post-inflammatory changes only.
After discussion with pulmonary team, it was decided not to start anti-TB medications and to treat her with oral steroids and topical steroids. There was a dramatic improvement in her vision six weeks after the treatment.
Discussion
BCG is a vaccine, prepared form live attenuated bovine tuberculosis bacillus. For intra-vesical use, it is injected via a catheter in the bladder, where it causes inflammation and increases natural killer cells via cell mediated immunity (T lymphocytes). These then recognise and destroy invading cells such as tumour cells in the bladder [Seal.JE] .
Intravesical BCG complications include painful or difficult micturition, frequency, abdominal cramps and pains, with or without haematuria. Less serious side effects include mild nausea, stomach pain and loss of appetite, diarrhoea, constipation, pneumonia, hepatitis, renal masses, mild skin rash and dizziness.
In animal experiments [Rutgard J], there were cases of ocular melanoma, ocular squomous cell carcinoma and of ocular equine sarcoid. However intravesical BCG usage in humans is not commonly associated with ocular complications. It is impossible to definitively prove that intravesicular BCG has caused our patient's bilateral panuveitis and optic neuritis. However, the patient's HLA B27 positivity in the absence of arthritis makes the diagnosis in favour of BCG induced ocular changes. Unfortunately, little evidence is available on the intravitreal pharmacokinetics. Nevertheless, the patient was diagnosed and treated successfully without any delay.
Conclusion
Patients who present with bilateral panuvetis post intravesical BCG will have a good visual outcome, as long as diagnosis and treatment are not delayed. Medical practitioners and Urologists need to be aware of the potential for ocular complications of BCG intravesical treatments and they should include this possibility in their procedural informed consent.
